EU medical technology industry: mid-2007 round-up of regulatory developments
This article was originally published in Clinica
For those returning from spending a few summer weeks at the beach or in other vacation pursuits, recent developments in the medtech industry may seem rather a blur. Much regulatory progress critical to the future of the medtech industry was made during the first half of 2007. Here, Amanda Maxwell summarises the main points in a whistle-stop tour
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.